학술논문
Expert eValuation of Efficacy and Rationality of Vildagliptin "EVER-Vilda": An Indian Perspective.
Document Type
Article
Author
Kalra, Sanjay; Zargar, Abdul Hamid; Sridhar, GR; Das, Ashok Kumar; Ahmed, Jamal; Mohan, Jagdish Chander; Vijayakumar, G; Kumar, Ajay; Sahay, Rakesh Kumar; Ayer, Vageesh; Pandit, Kaushik; Bantwal, Ganapathi; Srinivas, Arun; Unnikrishnan, AG; Jindal, Sushil; Ray, Saumitra; Baruah, Manash P; Ganguly, Kajal; Mittal, Sachin; Joshi, Ameya
Source
Subject
*DRUG efficacy
*GLYCOSYLATED hemoglobin
*COMBINATION drug therapy
*PROTEOLYTIC enzymes
*TYPE 2 diabetes
*MEDICAL protocols
*HEALTH care teams
*METFORMIN
*CHEMICAL inhibitors
*EVALUATION
*
*
*
*
*
*
*
*
*
Language
ISSN
1179-5514
Abstract
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy. [ABSTRACT FROM AUTHOR]